In addition,dexamethasone mouthwash formulation was prescribed as treatment infive patients with existing stomatitis. All patients achieved a significantreduction in the severity of stomatitis after starting the dexamethasone mouthwash formulation. In both cohorts, dexamethasone mouthwash formulationwas well tolerated and neither dose reduction nor discontinuationrelated to stomatitis was required. Dexamethasone mouthwash formulation could be consideredas a suitable alternative for stomatitis management. Dexamethasone mouthwash formulation could be considered as a suitable alternative for stomatitis management. To report on the results obtained from the 2019 SEFH NationalSurvey regarding the service portfolio, care activities, training programsand research work of Spanish hospital pharmacy departments. In March 2019, SEFH designed and distributed a questionnairecontaining 77 questions grouped into 8 domains to its 368 affiliatedhospital pharmacy departments. The questionnaire included an additionalsection on the activities carried out in 2017 and 2018. The overall response rate was 54.3%. https://www.selleckchem.com/products/Compk.html Sixty-nine percent ofhospitals were public and 75% were general hospitals. A total of 88.6%of hospital pharmacy departments provided pharmaceutical care toinpatients, whereas 77.5% and 65% treated outpatients and ambulatorypatients, respectively. Sterile formulations were prepared by 70.6%of pharmacy departments, while 12% measured drug levels in bodilyfluids; 76.9% of hospitals with more than 1,000 beds prepared pharmacokineticreports. In 2018, hospital pharmacies provided for a meanof 929 patients a month and 2,680 a year. main activities performed in Spanish hospital pharmacies,while there is still considerable room for improvement in the area of clinicalpharmacokinetics. Pharmacy departments are generally committed totraining as a key activity, while scientific output is still limited despite theincrease in the number of PhD pharmacist. Care of out-patients and medication compounding are increasingly the main activities performed in Spanish hospital pharmacies, while there is still considerable room for improvement in the area of clinical pharmacokinetics. Pharmacy departments are generally committed to training as a key activity, while scientific output is still limited despite the increase in the number of PhD pharmacist. Remdesivir has not shown survival benefit for patients withsevere COVID-19. However, subgroup analysis of ACTT-1 Study Groupshowed an apparent reduction in mortality for patients who requirednon‑high-flow oxygen. Presentation of SOLIDARITY study results wereassociated by a meta-analysis combining mortality results by subsets romrandomized clinical trials. The aim is a methodological assessment ofreliability and clinical applicability about findings by subgroups on theeffect of remdesivir on mortality in patients with COVID-19. A validated tool was used to evaluate the findings of subgroupanalyses in randomized clinical trials, including meta-analysis atached toSOLIDARITY study. It is structured in preliminary questions to reject subsetanalyses without relevant minimum conditions, and a specific checklist.The latter considers certain criteria statistical association, which encompassedp of interaction, prespecification of subgroups, sample size, numberof factors analyzed, and overall study result; biologicad interpretation of subgroup analysis suggestedtoo much uncertainty in hypothesis about remdesivir could reducemortality in patients with severe COVID-19 who required non-high- flowoxygen. It was probably a random finding. Therefore, a randomized clinicaltrial about effect of remdesivir in mortality in patients with COVID‑19and non-high-flow oxygen is essential. This structured interpretation of subgroup analysis suggested too much uncertainty in hypothesis about remdesivir could reduce mortality in patients with severe COVID-19 who required non-high- flow oxygen. It was probably a random finding. Therefore, a randomized clinical trial about effect of remdesivir in mortality in patients with COVID‑19 and non-high-flow oxygen is essential. To evaluate the efficacy and safety of anti-PD-1 and anti-PD-L1immunotherapy agents as monotherapy in patients with non-small cell lungcancer. This was a four-year retrospective observational study thatincluded all patients with non-small cell lung cancer treated with nivolumab,pembrolizumab, and atezolizumab in a third level hospital.Demographic, clinical (ECOG status, stage, PD-L1 expression level),therapeutic (drug, start date, line of treatment and number of cycles),efficacy (date and status at the end of follow-up) and toxicity variableswere collected. Data was extracted from the patient's electronic medicalrecord. Overall survival and progression-free survival rates for differentmonitoring times were calculated. The study included 80 patients, 35 on nivolumab, 32 on pembrolizumaband 13 on atezolizumab. The median overall survival was notachieved. Overall survival at 6, 12, 18 and 49 months in patients treatedwith nivolumab was 79.7%, 74.0%, 65.8% and 65.8%, respectively.Median progression-free surstudies. Further studies are requiredwith larger sample sizes and longer follow-up times to confirm thesefindings. Subjects showed a trend toward stabilization and chronification of the disease. A positive and considerable survival rate was observed, as compared with previous studies. Further studies are required with larger sample sizes and longer follow-up times to confirm these findings. To determine persistence of treatment with secukinumabacross its different indications. This is a retrospective descriptive observational study includingadult patients treated with secukinumab in its different indications from thedrug's introduction in November 2015 to October 2019. The variablesincluded were sex; age; diagnosis; initiation date; line of treatment; numberof patients who discontinued treatment and reason for discontinuation;overall persistence at 12 months; distribution of patients; and persistenceaccording to indication, line of treatment and reason for suspension. One-hundred forty-three patients were started on secukinumab,but only patients who had been in treatment at least 12 months before theend of the study were included. Mean patient age was 49.8 years (±12.6);52.9% were men. Fifty-six patients (53.8%) had discontinued treatment bythe end of the study, with a mean duration of treatment of 12.7 months(±10.2). The other patients (n = 48) continued with their therapy. Meanduration of treatment in these patients was 25.